{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-009308","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2025-07-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.116856+00:00","generated_at":"2026-05-18T04:54:14.820365+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Protalix appoints Gilad Mamlok as SVP & CFO effective Aug 24, 2025, succeeding Eyal Rubin","bullets":["Gilad Mamlok appointed Senior VP & CFO, effective August 24, 2025.","He succeeds Eyal Rubin, who resigned to pursue other opportunities.","Mamlok brings 30 years experience, previously CFO of TytoCare and Sol-Gel Technologies.","He receives monthly base salary of NIS 81,000 (~$24,066) plus discretionary bonus and options for 597,990 shares at $1.45.","Options vest over 3 years, accelerated upon change of control."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-009308","json":"https://secwatch.observer/filing/0001558370-25-009308.json","markdown":"https://secwatch.observer/filing/0001558370-25-009308.md","text":"https://secwatch.observer/filing/0001558370-25-009308.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837025009308/0001558370-25-009308-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837025009308/plx-20250613x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T04:54:14.820365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}